RYTM (Rhythm Pharmaceuticals) Insider Ownership: 1.98 % (As of Jul. 23, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RYTM Rhythm Pharmaceuticals Inc RYTM
57 GF Score
Price $102.71
GF Value $113.58
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Rhythm Pharmaceuticals Insider Ownership?

Rhythm Pharmaceuticals RYTM -1.33% 57 Insider Ownership is 1.98 % as of Jul. 23, 2026. GuruFocus rates RYTM with a GF Score™ of 57/100 and a GF Value™ of $113.58 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Rhythm Pharmaceuticals's insider ownership is 1.98%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Rhythm Pharmaceuticals's Institutional Ownership is 116.44%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Rhythm Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 99.22%.

Rhythm Pharmaceuticals Insider Ownership Historical Data

* Premium members only.

The historical data trend for Rhythm Pharmaceuticals's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rhythm Pharmaceuticals Insider Ownership Chart

Rhythm Pharmaceuticals Historical Data

The historical data trend for Rhythm Pharmaceuticals can be seen below:

2025-06-30 2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30
Insider Ownership 1.91 1.87 1.87 1.87 1.87 1.87 1.84 1.97 1.94 1.98
RYTM
57GF Score
Rhythm Pharmaceuticals Inc RYTM
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rhythm Pharmaceuticals Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 1.98 % mean?
Rhythm Pharmaceuticals (RYTM) has a Insider Ownership of 1.98 % as of Jul. 23, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Rhythm Pharmaceuticals and its competitors.
Is Rhythm Pharmaceuticals' Insider Ownership too high?
Rhythm Pharmaceuticals' current Insider Ownership is 1.98 %. Overall, Rhythm Pharmaceuticals has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Rhythm Pharmaceuticals' Insider Ownership compare to MIRM and SYRE?
Rhythm Pharmaceuticals' Insider Ownership of 1.98 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Rhythm Pharmaceuticals and its competitors. Rhythm Pharmaceuticals's current Insider Ownership is 1.98 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhythm Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Rhythm Pharmaceuticals (RYTM) is currently considered Modestly Undervalued. The stock's GF Value™ is $113.58, compared to a current price of $102.71 — trading 9.6% below its estimated fair value. The current Insider Ownership is 1.98 %. Rhythm Pharmaceuticals' overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Rhythm Pharmaceuticals (RYTM), the current Insider Ownership is 1.98 % as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rhythm Pharmaceuticals (RYTM) Overvalued in 2026?

Based on GuruFocus' analysis, Rhythm Pharmaceuticals stock appears to be undervalued. The current stock price of $102.71 is trading 9.6% below its estimated GF Value™ of $113.58. GuruFocus considers Rhythm Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for RYTM:

  • Insider Ownership: 1.98 %
  • GF Value™: $113.58 vs. price of $102.71 (9.6% below fair value)
  • GF Score™: 57/100 with 3 warning signs

No single metric tells the full story. See the RYTM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rhythm Pharmaceuticals Business Description

Other Exchanges 1RV:Germany
Address 222 Berkeley Street, 12th Floor, Boston, MA, USA, 02116
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
57GF Score

Get the complete analysis for RYTM

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$102.71
Price
$113.58
GF Value